SEARCH
Biovest International
Tampa, FL 33606 USA
Phone
Fax
Research Sector Biotech Specialty Pharma
Summary Description Manufacturer of biological drugs to treat cancer.
Management Francis E. O'Donnell, Jr. MD Chairman; Samuel S. Duffey, Esq. President and General Counsel; Mark Hirschel, Ph.D. Chief Scientific Officer; Alan Pearce, Chief Financial Officer; David D. Moser, Corporate Secretary; Click here for Financial Data
Keywords: Oncology, immunotherapy, Non-Hodgkin lymphoma
Updated: Nov. 29, 2016
Description
Biovest International is a majority-owned subsidiary of Accentia Biopharmaceuticals Inc., a vertically integrated specialty biopharmaceutical company with services to commercialize targeted therapeut......view more
Products / Services
Biovest is currently conducting clinical trials on BiovaxID(tm), a cancer immunotherapy vaccine for Non-Hodgkin's Lymphoma.......view more
Market / Customers
There are approximately 65,000 new cases of non-Hodgkin's lymphoma diagnosed each year in the US with a comparable number in Europe.......view more
Strategy
A core mission of Biovest is to its our expertise in hollow fiber to advance personalized medicine and make it a reality. In addition to manufacturing Biovest's proprietary vaccine, the company is wo...view more
Revenue / Funding
For over 10 years the company has operated the National Cell Culture Center (NCCC) under a grant from the National Institutes of Health....view more